Pharmacologic neuroprotection-Is xenon the light at the end of the tunnel?

Critical Care Medicine

Volumn 36, Issue 8, 2008, Pages 2477-2479

  Dworschak, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiac arrest; Functional defects; Global cerebral ischemia; Neuronal damage; Pharmacologic neuroprotection; Resuscitation; Xenon

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PENTOBARBITAL; XENON; NEUROPROTECTIVE AGENT;

ANESTHESIA; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN ISCHEMIA; BRAIN METABOLISM; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL RESEARCH; COGNITION; COGNITIVE DEFECT; CRITICALLY ILL PATIENT; DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; GRAY MATTER; HEART ARREST; HIPPOCAMPUS; HUMAN; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; INTENSIVE CARE; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; LONG TERM CARE; MINIMUM LUNG ALVEOLUS CONCENTRATION; MORTALITY; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; RESUSCITATION; RODENT; STROKE; SWINE; TREATMENT OUTCOME; ANIMAL; NOTE;

ANIMALS; BRAIN ISCHEMIA; HUMANS; NEUROPROTECTIVE AGENTS; XENON;

EID: 49949090854     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31818113d2     Document Type: Editorial

References (15)

1. Fries M, Nolte KW, Coburn M, et al: Xenon reduces neurohistological damage and improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med 2008; 36:2420-2426
2. Dworschak M, Franz M, Czerny M, et al: Release of neuron-specific enolase and S100 after implantation of cardioverters/defibrilla-tors. Crit Care Med 2003; 31:2085-2089
3. Murkin JM, Baird DL, Martzke JS, et al: Cognitive dysfunction after ventricular fibrillation during implantable cardiovertor/defi-brillator procedures is related to duration of the reperfusion interval. Anesth Analg 1997; 84:1186-1192
4. Weigl M, Tenze G, Steinlechner B, et al: A systematic review of currently available pharmacological neuroprotective agents as a sole intervention before anticipated or induced cardiac arrest. Resuscitation 2005; 65:21-39
5. Baumert JH, Falter F, Eletr D, et al: Xenon anaesthesia may preserve cardiovascular function in patients with heart failure. Acta Anaesthesiol Scand 2005; 49:743-749
6. Frietsch T, Bogdanski R, Blobner M, et al: Effects of xenon on cerebral blood flow and cerebral glucose utilization in rats. Anesthesiology 2001; 94:290-297
7. Rex S, Meyer PT, Baumert JH, et al: Positron emission tomography study of regional cerebral blood flow and flow-metabolism coupling during general anaesthesia with xenon in humans. Br J Anaesth 2008; 100:667-675
8. Schmidt M, Marx T, Armbruster S, et al: Effect of xenon on elevated intracranial pressure as compared with nitrous oxide and total intravenous anesthesia in pigs. Acta Anaesthesiol Scand 2005; 49:494-501
9. Coburn M, Baumert JH, Roertgen D, et al: Emergence and early cognitive function in the elderly after xenon or desflurane anaesthesia: A double-blinded randomized controlled trial. Br J Anaesth 2007; 98:756-762
10. Sanders RD, Ma D, Maze M: Xenon: Elemental anaesthesia in clinical practice. Br Med Bull 2005; 71:115-135
11. Schmidt M, Marx T, Gloggl E, et al: Xenon attenuates cerebral damage after ischemia in pigs. Anesthesiology 2005; 102:929-936
12. Coburn M, Maze M, Franks NP: The neuro-protective effects of xenon and helium in an in vitro model of traumatic brain injury. Crit Care Med 2008; 36:588-595
13. Goto T, Matsukawa T, Sessler DI, et al: Thermoregulatory thresholds for vasoconstric-tion in patients anesthetized with various 1-minimum alveolar concentration combinations of xenon, nitrous oxide, and isoflurane. Anesthesiology 1999; 91:626-632
14. Davis SM, Lees KR, Albers GW, et al: Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. Stroke 2000; 31:347-354
15. Hobbs C, Thoresen M, Tucker A, et al: Xenon and hypothermia combine addi-tively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke 2008; 39: 1307-1313